Keyphrases
Management Options
100%
Adjuvant Therapy
66%
Early Disease
66%
Clinical Trials
33%
Tumor
33%
Management Strategy
33%
Clinical Presentation
33%
Overall Survival
33%
Surgical Resection
33%
Epidemiology
33%
Mitotic Index
33%
Malignancy-associated
33%
Clinical Benefit
33%
Hysterectomy
33%
Histologic
33%
Multidrug-resistant
33%
Most Common Form
33%
Recurrent Disease
33%
Pathologic Characteristics
33%
Advanced Disease
33%
Oophorectomy
33%
Uterine Sarcoma
33%
Targeted Therapy
33%
Lymph Node Dissection
33%
Leiomyosarcoma
33%
Presenting Symptoms
33%
Tumor Necrosis
33%
Complete Surgical Resection
33%
Perimenopausal
33%
Cytological Atypia
33%
Pembrolizumab
33%
Nivolumab
33%
Mesenchymal Tumor
33%
Preoperative Diagnosis
33%
Pazopanib
33%
Medicine and Dentistry
Leiomyosarcoma
100%
Neoplasm
50%
Adjuvant Therapy
50%
Surgery
50%
Diseases
50%
Clinical Trial
25%
Overall Survival
25%
Cohort Effect
25%
Recurrent Disease
25%
Mitotic Index
25%
Cancer
25%
Hysterectomy
25%
Retroperitoneal Lymph Node Dissection
25%
Ovariectomy
25%
Targeted Therapy
25%
Tumor Necrosis
25%
Immunotherapy
25%
Chemotherapy
25%
Pazopanib
25%
Nivolumab
25%
Pembrolizumab
25%